Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.84 USD | +1.01% | +3.08% | +16.44% |
Apr. 11 | Collegium Pharmaceutical to Redeem $26.35 Million of Senior Notes | MT |
Feb. 26 | Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating | MT |
Financials (USD)
Sales 2024 * | 584M | Sales 2025 * | 596M | Capitalization | 1.17B |
---|---|---|---|---|---|
Net income 2024 * | 116M | Net income 2025 * | 144M | EV / Sales 2024 * | 2.3 x |
Net Debt 2024 * | 167M | Net cash position 2025 * | 42.16M | EV / Sales 2025 * | 1.9 x |
P/E ratio 2024 * |
12.1
x | P/E ratio 2025 * |
9.77
x | Employees | 197 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.62% |
Latest transcript on Collegium Pharmaceutical, Inc.
1 day | +1.01% | ||
1 week | +3.08% | ||
Current month | -7.68% | ||
1 month | -10.76% | ||
3 months | +7.02% | ||
6 months | +63.80% | ||
Current year | +16.44% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 59 | 01-12-31 | |
Joseph Ciaffoni
CEO | Chief Executive Officer | 53 | 17-05-30 |
Colleen Tupper
DFI | Director of Finance/CFO | 48 | 21-05-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Garen Bohlin
BRD | Director/Board Member | 76 | 14-12-31 |
Gino Santini
BRD | Director/Board Member | 66 | 12-07-23 |
John Freund
BRD | Director/Board Member | 70 | 14-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.25% | 29 M€ | -4.59% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 35.84 | +1.01% | 338,007 |
24-04-24 | 35.48 | -1.28% | 302,816 |
24-04-23 | 35.94 | +3.45% | 618,659 |
24-04-22 | 34.74 | -0.29% | 414,728 |
24-04-19 | 34.84 | +0.20% | 325,386 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.44% | 1.17B | |
+24.17% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+13.45% | 233B | |
+6.04% | 201B | |
-10.51% | 193B | |
-12.26% | 143B | |
-6.47% | 144B |
- Stock Market
- Equities
- COLL Stock